Abstract
Hormonal therapy forms part of the treatment of every intersex condition. For some conditions, such as salt-wasting congenital adrenal hyperplasia, hormonal replacement therapy is life saving because hormones necessary for survival (cortisol and aldosterone) are replaced. In contrast, other hormones such as androgens or mineralocorticoids are secreted in excessive amounts in congenital adrenal hyperplasia due to an enzyme imbalance, and the role of hormonal therapy is to suppress the unwanted hormone excess by exerting negative feedback. For patients with one of the many causes of hypogonadism, sex hormone replacement therapy may be prescribed to stimulate sexual development: growth of a hypoplastic penis in a young boy, pubertal changes (male or female), psychosexual development, and adult sexual behavior. It has equally important and highly beneficial effects on bone mineral density. Hormonal therapy is also used to treat the unborn child. For the last 20 years, prenatal dexamethasone treatment administered to the pregnant woman has been used to prevent the development of ambiguous genitalia in females with 21-hydroxylase deficiency. Outcome studies show this treatment to be well tolerated and, in general, efficacious.
Intersex conditions are, however, difficult to treat because they may intrinsically perturb complex aspects of the person’s gender identity, gender-role behavior, sexual orientation, sexual functioning, and psychologic adjustment. Furthermore, decisions made about the sex of an infant by doctors and parents do not always turn out to be correct; the person may grow up feeling uncertain about his or her gender identity, or worse still, harbor a sense of outrage about their life and treatment experiences. Such a person will have definite views about hormonal therapy when the time comes and skilful counseling will be needed. A vigorous debate about ethical aspects of current medical practices relating to intersex conditions has been waged for the last 7 years between certain patient advocacy organizations and the medical profession, and is expected to continue for some time. The quality of the debate will be improved by evidence. The results of a number of long-term follow-up studies have been published, and more are expected. The published studies show mixed, but mainly encouraging, results.
Similar content being viewed by others
References
Sax L. How common is intersex? A response to Anne Fausto-Sterling. J Sex Res 2002; 39: 174–8
Conte FA, Grumbach MM. Diagnosis and management of ambiguous external genitalia. Endocrinologist 2003; 13: 260–8
Gottlieb B, Beitel LK, Trifiro MA. Variable expressivity and mutation databases: the androgen receptor gene mutations database. Hum Mutat 2001; 17: 382–8
Wilson JD, Harrod MJ, Goldstein JL, et al. Familial incomplete male pseudo-hermaphroditism type I: evidence for androgen resistance in a family with the Reifenstein syndrome. N Engl J Med 1974; 290: 1097–103
Cameron FJ, Sinclair AH. Mutations in SRY and SOX9: testis-determining genes. Hum Mutat 1997; 9(5): 388–95
Baird PN, Santos A, Groves N, et al. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet 1992; 1: 301–5
Achermann JC, Ozisik G, Ito M, et al. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin Endocrinol Metab 2002; 87: 1829–33
Hageman RM, Cameron FJ, Sinclair AH. Mutation analysis of the SOX9 gene in a patient with campomelic dysplasia. Hum Mutat 1998; Suppl. 1: S112–3
Reardon W, Gibbons RJ, Winter RM, et al. Male pseudohermaphroditism in sibs with the alpha-thalassemia/mental retardation (ATR-X) syndrome. Am J Med Genet 1995; 55: 285–7
Bardoni B, Zanaria E, Guioli S, et al. A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal. Nat Genet 1994; 7: 497–501
Miller WL. Disorders of androgen biosynthesis. Semin Reprod Med 2002; 20: 205–15
Themmen APN, Verhoef-Post M. LH receptor defects. Semin Reprod Med 2002; 20: 199–204
Kuhnle U. True hermaphroditism. Endocrinologist 2003; 13: 214–8
Ludwig KS. The Mayer-Rokitansky-Kuster syndrome: an analysis of its morphology] and embryology: part I. Morphology. Arch Gynecol Obstet 1998; 262(1-2): 1–26
Josso N, Bellville C, Picard J-Y. Mutations of AMH and its receptors. Endocrinologist 2003; 13: 247–51
Achermann JC, Ito M, Ito M, et al. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans [letter]. Nat Genet 1999; 22: 125–6
Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43(4): 537–40
Francis RM. The effects of testosterone on osteoporosis in men. Clin Endocrinol 1999; 50: 411–4
Burris AS, Banks SM, Carter CS, et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13(4): 297–304
Gooren LJG. Psychological consequences. Semin Reprod Med 2002; 20: 285–95
Kuhnle U, Bullinger M, Schwarz HP. The quality of life in adult females with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients’ life. Eur J Pediatr 1995; 154: 708–16
Jaaskelainen J, Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr 2000; 89: 183–7
Meyer-Bahlburg HFL. Gender and sexuality in classic congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 155–71
Creighton SM, Minto CL, Steele SJ. Objective cosmetic and anatomical outcomes at adolescence of feminising surgery for ambiguous genitalia done in childhood. Lancet 2001; 358: 123–5
May B, Boyle M, Grant DB. A comparative study of sexual experiences: women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Health Psychol 1996; 1: 479–92
Meyer-Bahlburg HFL, Gruen RS, New MI, et al. Gender change from female to male in classical CAH. Horm Behav 1996; 30: 319–32
Warne GL. Jackie: a girl in crisis. Matern Child Health J 1992; 17: 359–60
Minto CL, Liao KL, Conway GS, et al. Sexual function in women with complete androgen insensitivity syndrome. Fertil Steril 2003; 80: 157–64
Hines M, Ahmed SF, Hughes IA. Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. Arch Sex Behav 2003; 32: 93–101
Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. Pediatrics 2002; 110: e31
Wisniewski AB, Migeon CJ. Long-term perspectives for 46,XY patients affected by complete androgen insensitivity syndrome or congenital micropenis. Semin Reprod Med 2002; 20(3): 297–304
Miller MA, Grant DB. Severe hypospadias with genital ambiguity: adult outcome after staged hypospadias repair. Br J Urol 1997; 80: 485–8
Wisniewski AB, Migeon CJ, Gearhart JP, et al. Congenital micropenis: long-term medical, surgical and psychosexual follow-up of individuals raised male or female. Horm Res 2001; 56: 3–11
Warne GL, Zajac JD. Disorders of sexual differentiation. Endocrinol Metab Clin North Am 1998; 27(4): 945–67
Clayton PE, Miller WL, Oberfield SE, et al. ESPE/LWPES CAH Working Group: consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 58: 188–95
Stikkelbroeck NM, Otten BJ, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 5721–8
Cutfield RG, Bateman JM, Odell WD. Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency). Fertil Steril 1983; 40(6): 809–14
Cabrera MS, Vogiatsi MG, New MI. Long-term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 3070–8
David M, Forest MG. Prenatal diagnosis and treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984; 105:799–801
Speiser PW. Prenatal treatment of congenital adrenal hyperplasia. J Urol 1999; 162: 534–6
Miller WL. Gene conversions, deletions and polymorphisms in congenital adrenal hyperplasia. Am J Hum Genet 1988; 42: 4–7
New MI, Carlson A, Obeid J, et al. Update: prenatal diagnosis for congenital adrenal hyperplasia in 595 pregnancies. Endocrinologist 2003; 13: 233–9
Forest MG, Dörr HG. Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 2003; 13: 252–9
Dardis A, Miller WL. Dexamethasone does not exert direct intracellular feedback on steroidogenesis in human adrenal NCI-H295A cells. J Endocrinol 2003 Oct; 179(1): 131–42
Spiliotis BE. Prenatal diagnosis and treatment of congenital adrenal hyperplasia and consequences in adults. J Pediatr Endocrinol Metab 2001; 14Suppl. 5: 1299–302
Bin-Abbas B, Conte FA, Grumbach MM, et al. Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. J Pediatr 1999; 134: 579–83
Arisaka O, Hoshi M, Kanazawa S, et al. Systemic effects of transdermal testosterone for the treatment of microphallus in children. Pediatr Int 2001; 43: 134–6
Choi SK, Han SW, Kim DH, et al. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 1993; 150: 657–60
Charmandari E, Dattani MT, Perry LA, et al. Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res 2001; 56: 177–81
Kuhn JM, Roca R, Laudat MH, et al. Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol 1983; 19: 513–20
Zacharin MR, Warne GL. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child 1997; 76: 495–9
McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91: 69–74
Grino PB, Isidro-Gutierrez RF, Griffin JE, et al. Androgen resistance associated with a qualitative abnormality of the androgen receptor and responsive to high dose androgen therapy. J Clin Endocrinol Metab 1989; 68: 578–84
Marcus R, Leary D, Schneider DL, et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85(3): 1032–7
Melo KF, Mendonca BB, Billerbeck AEC, et al. Clinical, hormonal, behavioural and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J Clin Endocrinol Metab 2003; 88: 3241–50
Slob AK, van der Werff ten Bosch JJ, van Hall EV, et al. Psychosexual functioning in women with complete testicular feminization: is androgen replacement therapy preferable to estrogen? J Sex Marital Ther 1993; 19: 201–9
Bertelloni S, Baroncelli GI, Federico G, et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998; 50: 309–14
Choi SK, Han SW, Kim DH, et al. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 1993; 150(2 Pt 2): 657–60
Odame I, Donaldson MD, Wallace AM, et al. Early diagnosis and management of 5 alpha-reductase deficiency. Arch Dis Child 1992; 67: 720–3
Kolon TF, Ferrer FA, McKenna PH. Clinical and molecular analysis of XX sex reversed patients. J Urol 1998; 160: 1169–72
Conway AJ, Handelsman DJ, Lording DW, et al. Use, misuse and abuse of androgens: the Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000; 172: 220–4
Krstic ZD, Smoljanic Z, Micovic Z, et al. Surgical treatment of the Mullerian duct remnants. J Pediatr Surg 2001; 36: 870–6
O’Neill S. Hormone replacement therapy. In: Brown P, Ku H, editors. Update on women’s health. Sydney: Alpha Biomedical Communications, 1995: 105–8
Rutgers JL, Scully RE. The androgen insensitivity syndrome (testicular feminization): a clinicopathological study of 43 cases. Int J Gynecol Pathol 1991; 10: 126–44
Mizunuma H, Sida M, Okano H, et al. Changes in bone mineral density after orchidectomy and hormone replacement therapy in individuals with androgen insensitivity syndrome. Hum Reprod 1998; 13: 2816–8
Zacharin M. Use of androgens and oestrogens in adolescents a review of hormone replacement treatment. J Pediatr Endocrinol Metab 2000; 13: 3–11
Togerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomised trials. JAMA 2001; 285: 2891–7
Togerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001;2: 1–11
Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin Endocrinol (Oxf) 2002; 56: 359–65
McDonnell CM, Coleman L, Zacharin MR. A 3-year prospective study to assess uterine growth in girls with Turner syndrome by pelvic ultrasound. Clin Endocrinol 2003; 58: 446–50
Carrascosa A, Gussinye M, Terradas P, et al. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. J Bone Miner Res 2000; 15: 2005–10
Marcus R, Leary D, Schreider DL, et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85: 1032–7
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701–12
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003; 289(24): 3243–53
Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8
Kemp LA, McDowell JA, editors. Paediatric pharmacopoeia. 13th ed. Melbourne: Royal Children’s Hospital, 2002: 136
Lin D, Sugawara T, Strauss III JF, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267: 1828–31
Auchus RJ, Miller WL. Molecular modeling of human P450cl7 (17-alpha-hydroxy-lase/ 17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocr 1999; 13: 1169–82
Clayton PE, Miller WL, Oberfield SE, et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 58: 188–95
Travitz J, Metzger DL. Antenatal treatment for classic 21-hydroxylase forms of congenital adrenal hyperplasia and the issues. Genet Med 1999; 1: 224–30
Warne GL, Zajac JD, MacLean HE. Androgen insensitivity syndrome in the era of molecular genetics and the internet. J Pediatr Endocrinol Metab 1998; 11: 3–9
Chase C. What is the agenda of the intersex patient advocacy movement? Endocrinologist 2003; 13: 240–2
Acknowledgments
The authors have no conflicts of interest that are directly relevant to the content of this review. No external funding was received by the authors and none of the authors is affiliated with or supported by any pharmaceutical company.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Warne, G.L., Grover, S. & Zajac, J.D. Hormonal Therapies for Individuals with Intersex Conditions. Mol Diag Ther 4, 19–30 (2005). https://doi.org/10.2165/00024677-200504010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200504010-00003